D3 receptor

Target id: 216

Nomenclature: D3 receptor

Family: Dopamine receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates.  » Email us

   GtoImmuPdb view: OFF :     Currently no data for D3 receptor in GtoImmuPdb

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 400 3q13.3 DRD3 dopamine receptor D3 52
Mouse 7 446 16 B4 Drd3 dopamine receptor D3 44
Rat 7 446 11q21 Drd3 dopamine receptor D3 132
Previous and Unofficial Names
D3 receptor | dopamine D3 receptor | dopaminergic receptor D3 | D3R
Database Links
Specialist databases
GPCRDB drd3_human (Hs), drd3_mouse (Mm), drd3_rat (Rn)
Other databases
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
GenitoUrinary Development Molecular Anatomy Project
Human Protein Atlas
KEGG Gene
OMIM
Orphanet
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Structure of the human dopamine D3 receptor in complex with eticlopride
PDB Id:  3PBL
Ligand:  eticlopride
Resolution:  2.89Å
Species:  Human
References:  27
Natural/Endogenous Ligands
dopamine

Download all structure-activity data for this target as a CSV file

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]7-OH-DPAT Hs Agonist 9.6 pKd 120
pKd 9.6 (Kd 2.7x10-10 M) [120]
[3H]7-OH-DPAT Rn Agonist 9.1 pKd 88
pKd 9.1 (Kd 7.94x10-10 M) [88]
[3H]PD128907 Hs Agonist 9.0 pKd 4
pKd 9.0 (Kd 9.9x10-10 M) [4]
cariprazine Hs Partial agonist 10.1 pKi 2
pKi 10.1 (Ki 9x10-11 M) [2]
Description: Binding affinity to human dopamine D3 receptor
lisuride Hs Partial agonist 9.6 pKi 102
pKi 9.6 [102]
cabergoline Hs Partial agonist 9.1 pKi 102
pKi 9.1 [102]
terguride Hs Partial agonist 9.0 pKi 102
pKi 9.0 [102]
BP 897 Hs Partial agonist 9.0 pKi 114
pKi 9.0 (Ki 1x10-9 M) [114]
roxindole Hs Partial agonist 8.9 pKi 102
pKi 8.9 [102]
pramipexole Hs Full agonist 8.4 – 8.7 pKi 97,123
pKi 8.4 – 8.7 [97,123]
(-)-N-porphynorapomorphine Hs Full agonist 8.4 – 8.7 pKi 45,123
pKi 8.4 – 8.7 [45,123]
rotigotine Hs Agonist 8.4 pKi 43
pKi 8.4 (Ki 4x10-9 M) [43]
pergolide Hs Partial agonist 8.3 pKi 102,131
pKi 8.3 (Ki 5.01x10-9 M) [102,131]
7-OH-DPAT Hs Full agonist 7.1 – 8.4 pKi 19,31,45,89,123
pKi 7.1 – 8.4 (Ki 7.94x10-8 – 3.98x10-9 M) [19,31,45,89,123]
ropinirole Hs Agonist 7.7 pKi 58
pKi 7.7 (Ki 1.9x10-8 M) [58]
apomorphine Rn Partial agonist 7.7 pKi 132
pKi 7.7 [132]
7-trans-OH-PIPAT Hs Full agonist 7.7 pKi 31
pKi 7.7 [31]
bromocriptine Hs Partial agonist 7.1 – 8.2 pKi 45,102,123
pKi 7.1 – 8.2 [45,102,123]
PD 128907 Hs Full agonist 7.6 – 7.7 pKi 117,123
pKi 7.6 – 7.7 (Ki 2.51x10-8 – 1.99x10-8 M) [117,123]
quinpirole Rn Full agonist 7.3 – 7.8 pKi 19,132
pKi 7.3 – 7.8 [19,132]
quinelorane Hs Full agonist 7.2 – 7.4 pKi 103,131
pKi 7.2 – 7.4 [103,131]
quinpirole Hs Full agonist 6.4 – 8.0 pKi 19,97,103,111,123,131-132,143
pKi 6.4 – 8.0 (Ki 3.98x10-7 – 1x10-8 M) [19,97,103,111,123,131-132,143]
bromocriptine Rn Full agonist 7.1 pKi 132
pKi 7.1 [132]
dopamine Hs Full agonist 6.4 – 7.3 pKi 19,45,123,132
pKi 6.4 – 7.3 [19,45,123,132]
apomorphine Hs Partial agonist 6.1 – 7.6 pKi 19,45,102,123,131
pKi 6.1 – 7.6 [19,45,102,123,131]
compound 3 [PMID: 23134120] Hs Agonist 6.8 pKi 135
pKi 6.8 (Ki 1.68x10-7 M) [135]
piribedil Hs Partial agonist 6.6 pKi 102
pKi 6.6 [102]
HS665 Hs Agonist 6.6 pKi 135
pKi 6.6 (Ki 2.82x10-7 M) [135]
vilazodone Hs Agonist 7.2 pIC50 59
pIC50 7.2 (IC50 7.1x10-8 M) [59]
PF-592379 Hs Agonist 6.7 pIC50 33
pIC50 6.7 (IC50 2.15x10-7 M) [33]
View species-specific agonist tables
Agonist Comments
PF-592379 has no measurable binding to D1, D2 or D5 receptors [33].
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]nemonapride Hs Antagonist 10.3 pKd 90
pKd 10.3 [90]
[3H]spiperone Rn Antagonist 9.9 pKd 61,155
pKd 9.9 (Kd 1.25x10-10 M) [61,155]
S33084 Hs Antagonist 9.6 pKi 101
pKi 9.6 (Ki 2.5x10-10 M) [101]
perospirone Hs Antagonist 9.6 pKi 131
pKi 9.6 (Ki 2.8x10-10 M) [131]
nafadotride Hs Antagonist 9.5 pKi 124
pKi 9.5 (Ki 3x10-10 M) [124]
nemonapride Hs Antagonist 9.2 – 9.3 pKi 89,140
pKi 9.2 – 9.3 [89,140]
spiperone Hs Antagonist 9.2 pKi 132
pKi 9.2 [132]
PG01037 Hs Antagonist 9.2 pKi 56
pKi 9.2 [56]
flupentixol Hs Antagonist 9.0 pKi 45
pKi 9.0 (Ki 1.1x10-9 M) [45]
eticlopride Hs Antagonist 8.8 pKi 89,140
pKi 8.8 [89,140]
NGB 2904 Hs Antagonist 8.8 pKi 147
pKi 8.8 [147]
sertindole Hs Antagonist 8.0 – 8.8 pKi 7,126,128
pKi 8.0 – 8.8 (Ki 1x10-8 – 1.6x10-9 M) [7,126,128]
prochlorperazine Hs Antagonist 8.4 pKi 10
pKi 8.4 (Ki 4.45x10-9 M) [10]
zotepine Hs Antagonist 8.2 pKi 126
pKi 8.2 (Ki 6.4x10-9 M) [126]
(+)-sulpiride Hs Antagonist 8.1 pKi 91
pKi 8.1 (Ki 7.99x10-9 M) [91]
haloperidol Hs Antagonist 7.5 – 8.6 pKi 45,129,131,142
pKi 7.5 – 8.6 [45,129,131,142]
SB 277011-A Hs Antagonist 8.0 pKi 118
pKi 8.0 (Ki 1x10-8 M) [118]
raclopride Hs Antagonist 7.9 pKi 103
pKi 7.9 [103]
pimozide Hs Antagonist 7.0 – 8.6 pKi 45,131
pKi 7.0 – 8.6 [45,131]
loxapine Hs Antagonist 7.7 pKi 128
pKi 7.7 (Ki 2.1x10-8 M) [128]
mesoridazine Hs Antagonist 7.6 pKi 30
pKi 7.6 (Ki 2.3x10-8 M) [30]
raclopride Rn Antagonist 7.5 pKi 132
pKi 7.5 [132]
(+)-butaclamol Rn Antagonist 7.3 – 7.5 pKi 19
pKi 7.3 – 7.5 [19]
pimozide Rn Antagonist 7.4 pKi 132
pKi 7.4 [132]
amisulpride Rn Antagonist 7.4 pKi 132
pKi 7.4 [132]
(+)-S-14297 Hs Antagonist 6.9 – 7.9 pKi 99,103
pKi 6.9 – 7.9 (Ki 1.26x10-7 – 1.3x10-8 M) [99,103]
(+)-butaclamol Hs Antagonist 6.7 – 8.0 pKi 45,117,140
pKi 6.7 – 8.0 [45,117,140]
chlorpromazine Hs Antagonist 7.2 – 7.5 pKi 45,131
pKi 7.2 – 7.5 [45,131]
domperidone Hs Antagonist 7.1 – 7.6 pKi 45,131
pKi 7.1 – 7.6 [45,131]
sulpiride Hs Antagonist 6.8 – 7.8 pKi 19
pKi 6.8 – 7.8 (Ki 1.42x10-7 – 1.4x10-8 M) [19]
chlorpromazine Rn Antagonist 7.2 pKi 132
pKi 7.2 [132]
(+)-UH232 Hs Antagonist 7.0 – 7.4 pKi 45,132
pKi 7.0 – 7.4 [45,132]
(-)-sulpiride Hs Antagonist 6.7 – 7.7 pKi 45,131,140
pKi 6.7 – 7.7 (Ki 2.07x10-7 – 2x10-8 M) [45,131,140]
haloperidol Rn Antagonist 7.0 pKi 132
pKi 7.0 [132]
risperidone Hs Antagonist 7.0 pKi 103
pKi 7.0 [103]
(+)-UH232 Rn Antagonist 7.0 pKi 132
pKi 7.0 [132]
domperidone Rn Antagonist 7.0 pKi 132
pKi 7.0 [132]
promazine Hs Antagonist 6.8 pKi 20
pKi 6.8 (Ki 1.59x10-7 M) [20]
trans-flupenthixol Hs Antagonist 6.5 pKi 45
pKi 6.5 (Ki 3x10-7 M) [45]
(+)-sulpiride Rn Antagonist 6.4 pKi 132
pKi 6.4 [132]
(+)-AJ76 Hs Antagonist 5.9 – 6.2 pKi 103,131
pKi 5.9 – 6.2 [103,131]
(+)-AJ76 Rn Antagonist 6.0 pKi 132
pKi 6.0 [132]
clozapine Hs Antagonist 5.2 – 6.3 pKi 45,131
pKi 5.2 – 6.3 [45,131]
clozapine Rn Antagonist 5.7 pKi 132
pKi 5.7 [132]
View species-specific antagonist tables
Allosteric Modulators
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
SB269652 Hs Negative ~9.0 pKi 46
pKi ~9.0 (Ki ~1x10-9 M) [46]
Primary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family Adenylate cyclase inhibition
Potassium channel
References:  28,85,115-116,127
Tissue Distribution
Ventral striatum/nucleus accumbens > neostriatum, cerebral cortex, cerebellar cortex.
Species:  Human
Technique:  Autoradiography.
References:  60,75
Brain: nucleus accumbens and islands of Calleja.
Species:  Human
Technique:  in situ hybridization.
References:  77
Brain: mesencephalic dopamine neurons in substantia nigra and ventral tegmental area.
Species:  Rat
Technique:  In situ hybridization.
References:  42
Kidney: proximal tubules
Species:  Rat
Technique:  Immunohistochemistry
References:  107
Brain: Post-synaptic elements of asymmetric synapses of the nucleus accumbens
Species:  Rat
Technique:  Immuno-electron microscopy
References:  86,133
Brain: islands of Cajella, olafactory bulb, pituitary intermediate lobe > nucleus accumbens, molecular layer of the vestibulocerebellum, substantia nigra pars compacta.
Species:  Rat
Technique:  Autoradiography and in situ hybridization.
References:  13,41,49,76,82,88,110,119
Accumbens nucleus, islands of Calleja, bed nucleus of the stria terminalis, hippocampus, mammillary nuclei, substantia nigra.
Species:  Rat
Technique:  in situ hybridization.
References:  15
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of adenylyl cyclase activity in CHO cells transfected with the rat D3 receptor.
Species:  Rat
Tissue:  CHO cells.
Response measured:  Inhibition of adenylyl cyclase.
References:  28
Measurement of extracellular acidification rates in CHO cells transfected with the rat D3 receptor.
Species:  Rat
Tissue:  CHO cells.
Response measured:  Increase in extracellular acidification rates.
References:  28
Measurement of extracellular acidification and D3 receptor membrane density in C6 glioma cells transfected with the rat D3 receptor.
Species:  Rat
Tissue:  C6 glioma cells.
Response measured:  Increase in extracellular acidification rate and receptor density.
References:  35
Measurement of c-fos activation and increased mitogenesis in neuroblastoma-glioma hybrid cells (NG108-15) transfected with the human D3 receptor.
Species:  Human
Tissue:  NG108-15 cells.
Response measured:  Increase in c-fos activation and mitogenesis.
References:  115
Measurement of cAMP accumulation in cultured Xenopus laevis melanophores transfected with the human D3 receptor.
Species:  Human
Tissue:  Cultured Xenopus laevis melanophores.
Response measured:  Inhibition of cAMP accumulation.
References:  116
Measurement of whole-cell potassium current in NG108-15 cells tranfected with the human D3 receptor.
Species:  Human
Tissue:  NG108-15 cells.
Response measured:  Reduction of peak whole-cell potassium current.
References:  85
Measurement of activation of GIRK1 in Xenopus oocytes transfected with the human D3 receptor.
Species:  Human
Tissue:  Xenopus oocytes.
Response measured:  Activation of GIRK1.
References:  146
Measurement of mitogenesis in NG108-15 cells transfected with the human D3 receptor.
Species:  Human
Tissue:  NG108-15 cells.
Response measured:  Increase in mitogenesis.
References:  123
Measurement of melanocyte aggregation in Xenopus melanocytes transfected with the human D3 receptor.
Species:  Human
Tissue:  Xenopus melanocytes.
Response measured:  Stimulation of melanocyte aggregation.
References:  18,117
Measurement of extracellular acidification in CHO cells transfected with the human D3 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Increase in extracellular acidification.
References:  18
Measurement of activation of an 85 pS K+ channel known to be activated by dopamine and the "D2-like" agonist quinpirole.
Species:  Human
Tissue:  Freshly dissociated rat caudate-putamen neurons.
Response measured:  Activation of K+ channel.
References:  84
Measurement of dopamine release from a mesencephalic clonal cell line transfected with the D3 receptor.
Species:  Human
Tissue:  Neuronal mesencephalic MN9D cells.
Response measured:  Inhibition of dopamine release.
References:  141
Measurement of K+-stimulated tyrosine hydroxylase activity in D3 receptor-expressing MN9D cells.
Species:  Human
Tissue:  MN9D cells
Response measured:  Decrease in K+-stimulated tyrosine hydroxylase activity.
References:  108
Measurement of cAMP levels in HEK 293 cells transfected with the human D3 receptor.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  93
Measurement of Cl- currents in Xenopus oocytes transfected with murine D3L and D3S receptors.
Species:  Mouse
Tissue:  Xenopus oocytes.
Response measured:  Stimulation of Cl- influx.
References:  130
Measurement of β-arrestin translocation in CHO cells with the human D3 receptor.
Species:  Human
Tissue:  CHO cells
Response measured:  β-arrestin translocation
References:  12,96,149
Physiological Functions
Inhibition of dopamine release.
Species:  Rat
Tissue:  In vivo.
References:  38,117
Stimulation of the D3 receptor produces an aversive effect in a conditioned place-preference paradigm.
Species:  Rat
Tissue:  In vivo.
References:  26
Activation increases cell division.
Species:  Rat
Tissue:  CHO cells.
References:  28
Inhibition of locomotor activity.
Species:  Rat
Tissue:  In vivo.
References:  3,37,39,50,65,67,69,83,94,117,124,138-139,144-145
Modulation of motor activity.
Species:  Mouse
Tissue:  In vivo.
References:  136
Stimulation of yawning and hypothermia.
Species:  Rat
Tissue:  In vivo.
References:  3,38,67,72,98-99,103
Modulation of sniffing behaviour.
Species:  Rat
Tissue:  In vivo.
References:  37
Modulation of penile erection and ejaculatory behaviour.
Species:  Rat
Tissue:  In vivo.
References:  22,72
Modulation of self-administration of cocaine.
Species:  Rat
Tissue:  In vivo.
References:  21
Modulation of self-stimulation of the ventral tegmental area.
Species:  Rat
Tissue:  In vivo.
References:  39
Modulation of reinforcing effects of cocaine and d-amphetamine.
Species:  Rat
Tissue:  In vivo.
References:  68
Stimulation of the D3 receptor decreases the rate of food-reinforced responding in a fixed-ratio operant paradigm.
Species:  Rat
Tissue:  In vivo.
References:  122
Hyperpolarization of neurons and inhibition of cell firing.
Species:  Rat
Tissue:  Substantia nigra pars compacta and ventral tegmental area of rat brain slices.
References:  16
A D3 agonist with relative selectivity for the dopamine D3 receptor, inhibits the firing of both A9 and A10 dopamine neurons and causes current-dependent inhibitions of spontaneously active or glutamate-driven caudate-putamen and nucleus accumbens neurons.
Species:  Rat
Tissue:  Substantia nigra pars compacta and ventral tegmental area dopamine neurons, and caudate-putamen and nucleus accumbens neurons in vivo.
References:  84
Systemic administration of a D3 receptor agonist decreases extracellular dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in the nucleus accumbens and dopaminergic neuronal activity in the ventral tegmental area.
Species:  Rat
Tissue:  In vivo.
References:  40
A D3 agonist inhibits substantia nigra pars compacta dopamine single cell firing.
Species:  Rat
Tissue:  In vivo.
References:  71
A D3 agonist inhibits ventral tagmental area dopamine single cell firing.
Species:  Rat
Tissue:  In vivo.
References:  80
Administration of a D3 agonist to freely moving rats decreases dialysate levels of dopamine in the nucleus accumbens.
Species:  Rat
Tissue:  In vivo.
References:  121
Application of a D3 receptor agonist reduces electrically-evoked dopamine release from the nucleus accumbens and striatum.
Species:  Rat
Tissue:  Nucleus accumbens and striatal slices.
References:  152
Modulation of dopamine synthesis.
Species:  Rat
Tissue:  In vivo.
References:  6,47,54,117
Blockade of the D3 receptor inhibits dizocilpine (MK-801)-induced hyperactivity.
Species:  Mouse
Tissue:  In vivo.
References:  81
Blockade of the D3 receptor disrupts drug-associated cue-induced craving and stress-induced craving.
Species:  Rat
Tissue:  In vivo.
References:  5,25,48,51,112,114,148
Blockade of the D3 receptor enhances monoaminergic and cholinergic neurotransmission.
Species:  Rat
Tissue:  In vivo.
References:  73-74,100-101
Application of a D3 receptor agonist reduces electrically-evoked dopamine release from the nucleus accumbens and striatum.
Species:  Rat
Tissue:  Nucleus accumbens and striatal slices.
References:  152
Modulation by the D3 receptor of drug-induced place preference.
Species:  Rat
Tissue:  In vivo.
References:  8,11,24,57,62
Reciprocal regulation of D3 receptor and NMDA receptor through Ca2+/calmodulin-dependent protein kinase II
Species:  Rat
Tissue:  GST-constructs and nucleus accumbens extracts.
References:  86
Selective D3 antagonists induced positive cerebral blood volume (CBV) changes whereas D3 agonism using 7-OH-DPAT induced negative CBV changes.
Species:  Rat
Tissue:  Nucleus accumbens, antero-medial striatum, cingulate cortex, thalamus, interpeduncular region and hypothalamus.
References:  29
Regulation of renal function and blood pressure by D3 receptors.
Species:  Rat
Tissue:  In vivo.
References:  87,153-154
Physiological Consequences of Altering Gene Expression
D3 receptor knockout mice exhibit altered circadian pattern in spinal dopamine synthesis.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  32
D3 receptor knockout mice exhibit higher basal levels of extracellular dopamine compared to the wild-type.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  34,64
D3 receptor knockout mice display enhanced hyperactivity when compared to the wild-type, although these effects may be limited.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  1,14,151
D3 receptor knockout mice display a transient increase in activity in a novel environment compared with wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  70,150
D3 receptor knockout mice exhibit increased behavioural sensitivity to combined injections of D1 and D2 class receptor agonists, cocaine and amphetamine.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  151
D3 receptor knockout mice exhibit reduced anxiety.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  137
D3 receptor knockout mice exhibit renin-dependent hypertension.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  9
D3 receptor knockout mice exhibit increased gene expression in striatal neurons following acute administration of cocaine.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  23
D3 receptor knockout mice exhibit aggravation of the development of physical dependence on ethanol.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  106
D3 receptor knockout mice exhibit increased morphine-induced rewarding effects and potentiation of morphine-induced hyperlocomotion.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  105
D3 receptor knockout mice display similar effects (reward/intake) of ethanol as wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  17
D3 receptor knockout mice exhibit increased D1/D2 receptor-mediated intracellular signalling.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  104
D3 receptor knockout mice exhibit increased adiposity induced by a high-fat diet.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  95
D3 receptor knockout mice exhibit neuroadaptive changes which support the role of D3 receptors as autoreceptors.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  79
D3 receptor knockout mice display increased susceptibility to cocaine addition
Species:  Mouse
Tissue: 
Technique:  Gene knockout
References:  134
Dopamine is more efficacious at the D3 receptor Gly9 compared to Ser9 variant.
Species:  Human
Tissue:  HEK293 cells
Technique:  Binding, adenylate cyclase inhibition, MAPK phosphorylation
References:  63
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
+|Cm|Drd3tm1Stl Cm/+,Drd3tm1Stl/Drd3tm1Stl
involves: 101/H * 129S2/SvPas * C3H/HeH * C3H/HeSn * C57BL/6J
MGI:88424  MGI:94925  MP:0009748 abnormal behavioral response to addictive substance PMID: 19840852 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0001454 abnormal cued conditioning behavior PMID: 9354330 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001905 abnormal dopamine level PMID: 10391470 
Drd2tm1Schm|Drd3+|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001905 abnormal dopamine level PMID: 10391470 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0005449 abnormal food intake PMID: 15084447 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0006001 abnormal intestinal transit time PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0006003 abnormal large intestinal transit time PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2tm1Schm|Drd3+|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2+|Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2+,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0001666 abnormal nutrient absorption PMID: 16525059 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0000676 abnormal water content PMID: 15084447 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001262 decreased body weight PMID: 10391470 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0001262 decreased body weight PMID: 16525059 
Drd3tm1Rmw Drd3tm1Rmw/Drd3tm1Rmw
involves: 129P2/OlaHsd
MGI:94925  MP:0005643 decreased dopamine level PMID: 12044470 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0001442 decreased grooming behavior PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0001442 decreased grooming behavior PMID: 8700864 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001505 hunched posture PMID: 10391470 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0001399 hyperactivity PMID: 9354330 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0001399 hyperactivity PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0001399 hyperactivity PMID: 8700864 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0005669 increased circulating leptin level PMID: 15084447 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0003867 increased defecation PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0003911 increased drinking behavior PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0003909 increased eating behavior PMID: 16525059 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0001415 increased exploration in new environment PMID: 9354330 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0001415 increased exploration in new environment PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0001415 increased exploration in new environment PMID: 8700864 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0005458 increased percent body fat PMID: 15084447 
Drd3tm1Rmw Drd3tm1Rmw/Drd3tm1Rmw
involves: 129P2/OlaHsd
MGI:94925  MP:0001409 increased stereotypic behavior PMID: 12044470 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0005455 increased susceptibility to weight gain PMID: 15084447 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6
MGI:94925  MP:0010024 increased total body fat amount PMID: 15084447 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0002574 increased vertical activity PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6
MGI:94925  MP:0002574 increased vertical activity PMID: 8700864 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0002082 postnatal lethality PMID: 10391470 
Clinically-Relevant Mutations and Pathophysiology
Disease:  Major affective disorder 1; MAFD1
Synonyms: Bipolar affective disorder
Manic depressive-psychosis
OMIM: 125480
Role: 
References:  109
Disease:  Schizophrenia
Disease Ontology: DOID:5419
OMIM: 181500
Orphanet: ORPHA3140
Role: 
References:  36,66,92
Disease:  Tremor, hereditary essential, 1; ETM1
Synonyms: Essential tremor [Disease Ontology: DOID:4990]
Hereditary essential tremor [Orphanet: ORPHA862]
Disease Ontology: DOID:4990
OMIM: 190300
Orphanet: ORPHA862
Comments: 
References:  63
Click column headers to sort
Type Species Amino acid change Nucleotide change Description Reference
Missense Human S9G Gain of function mutation. Functional variant of the dopamine D3 receptor which is associated with risk and age-at-onset of essential tremor 63
General Comments
Alternative splicing leads to a 425aa isoform in mouse [44] and several shorter presumably inactive isoforms in rat [53] and human [125]. Two polymorphic variants [Ser9] and [Gly9] in human [78]. The organization of the coding sequence of the human gene has been established [55]. Anti-psychotic drugs display closely similar or slightly lower antagonist affinity at D3 compared to D2 receptors. S(+)14297, initially reported as a D3 receptor antagonist [103] displays full agonist activity in two functional assays [113].

References

Show »

1. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda E B, Lee EJ, Cool MH, Sibley DR, Gerfen CR, Westphal H, Fuchs S. (1996) A targeted mutation of the D3 receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. U.S.A.93: 1945-1949. [PMID:8700864]

2. Agai-Csongor E, Domány G, Nógrádi K, Galambos J, Vágó I, Keserű GM, Greiner I, Laszlovszky I, Gere A, Schmidt E et al.. (2012) Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg. Med. Chem. Lett.22 (10): 3437-40. [PMID:22537450]

3. Ahlenius S, Salmi P. (1994) Behavioral and biochemical effects of the dopamine D3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat. Eur J Pharmacol260: 177-181. [PMID:7988642]

4. Akunne HC, Towers P, Ellis GJ, Dijkstra D, Wikström H, Heffner TG, Wise LD, Pugsley TA. (1995) Characterization of binding of [3H]PD 128907, a selective dopamine D3 receptor agonist ligand, to CHO-K1 cells. Life Sci.57 (15): 1401-10. [PMID:7674830]

5. Andreoli M, Tessari M, Pilla M, Valerio E, Hagan JJ, Heidbreder CA. (2003) Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology28 (7): 1272-80. [PMID:12700694]

6. Aretha CW, Sinha A, Galloway MP. (1995) Dopamine D3-preferring ligands act at synthesis modulating autoreceptors. J Pharmacol Exp Ther274: 609-613. [PMID:7636720]

7. Arnt J, Skarsfeldt T. (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology18 (2): 63-101. [PMID:9430133]

8. Ashby Jr CR, Paul M, Gardner EL, Heidbreder CA, Hagan JJ. (2003) Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse48 (3): 154-6. [PMID:12645041]

9. Asico LD, Ladines C, Fuchs S, Accili D, Carey RM, Semeraro C, Pocchiari F, Felder RA Eisner G, Jose PA. (1998) Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J. Clin. Invest.102: 493-498. [PMID:9691085]

10. Auerbach SS, DrugMatrix® and ToxFX® Coordinator National Toxicology Program. National Toxicology Program: Dept of Health and Human Services. Accessed on 02/05/2014. Modified on 02/05/2014. DrugMatrix, https://ntp.niehs.nih.gov/drugmatrix/index.html

11. Aujla H, Beninger RJ. (2005) The dopamine D(3) receptor-preferring partial agonist BP 897 dose-dependently attenuates the expression of amphetamine-conditioned place preference in rats. Behav Pharmacol16 (3): 181-6. [PMID:15864073]

12. Banala AK, Levy BA, Khatri SS, Furman CA, Roof RA, Mishra Y, Griffin SA, Sibley DR, Luedtke RR, Newman AH. (2011) N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. J. Med. Chem.54 (10): 3581-94. [PMID:21495689]

13. Booze RM, Wallace DR. (1995) Dopamine D2 and D3 receptors in the rat striatum and nucleus accumbens: use of 7-OH-DPAT and [125I]-iodosulpride. Synapse19: 1-13. [PMID:7709338]

14. Boulay D, Depoortere R, Rostene W, Perrault G, Sanger DJ. (1999) Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice. Neuropharmacology38: 555-565. [PMID:10221759]

15. Bouthenet M-L, Souil E, Martres M-P, Sokoloff P, Giros B, Schwartz J-C. (1991) Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with D2 receptor mRNA. Brain Res.564: 203-219. [PMID:1839781]

16. Bowery B, Rothwell LA, Seabrook GR. (1994) Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area. Br J Pharmacol112: 873-880. [PMID:7921615]

17. Boyce-Rustay JM, Risinger FO. (2003) Dopamine D3 receptor knockout mice and the motivational effects of ethanol. Pharmacol Biochem Behav75: 373-379. [PMID:12873629]

18. Boyfield I, Winn F, Coldwell M. (1996) Comparison of agonist potencies at human dopamine D2 and D3 receptors, expressed in the same cell line, using the Cytosensor Microphysiometer. Biochem Soc Trans24: 57S-57S. [PMID:8674731]

19. Burris KD, Pacheco MA, Filtz TM, Kung MP, Kung HF, Molinoff PB. (1995) Lack of discrimination by agonists for D2 and D3 dopamine receptors. Neuropsychopharmacology12: 335-345. [PMID:7576010]

20. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U et al.. (2005) Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J. Pharmacol. Exp. Ther.315 (3): 1278-87. [PMID:16135699]

21. Caine SB, Koob GF. (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science260: 1814-1816. [PMID:8099761]

22. Carlsson A, Lindqvist M, Magnusson M. (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature180: 1200-. [PMID:13483658]

23. Carta AR, Gerfen CR, Steiner H. (2000) Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice. Neuroreport11: 2395-2399. [PMID:10943692]

24. Cervo L, Burbassi S, Colovic M, Caccia S. (2005) Selective antagonist at D3 receptors, but not non-selective partial agonists, influences the expression of cocaine-induced conditioned place preference in free-feeding rats. Pharmacol. Biochem. Behav.82 (4): 727-34. [PMID:16405981]

25. Cervo L, Cocco A, Petrella C, Heidbreder CA. (2007) Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat. Int. J. Neuropsychopharmacol.10 (2): 167-81. [PMID:16426478]

26. Chaperon F, Thiébot MH. (1996) Effects of dopaminergic D3-receptor-preferring ligands on the acquisition of place conditioning in rats. Behav Pharmacol7: 105-109. [PMID:11224401]

27. Chien EY, Liu W, Zhao Q, Katritch V, Han GW, Hanson MA, Shi L, Newman AH, Javitch JA, Cherezov V et al.. (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science330 (6007): 1091-5. [PMID:21097933]

28. Chio CL, Lajiness ME, Huff RM. (1994) Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol45: 51-60. [PMID:8302280]

29. Choi JK, Mandeville JB, Chen YI, Grundt P, Sarkar SK, Newman AH, Jenkins BG. (2010) Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonists. Psychopharmacology (Berl.)212 (1): 59-72. [PMID:20628733]

30. Choi S, Haggart D, Toll L, Cuny GD. (2004) Synthesis, receptor binding and functional studies of mesoridazine stereoisomers. Bioorg. Med. Chem. Lett.14 (17): 4379-82. [PMID:15357957]

31. Chumpradit S, Kung MP, Vessotskie J, Foulon C, Mu M, Kung HF. (1994) Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors. J Med Chem37: 4245-4250. [PMID:7990123]

32. Clemens S, Sawchuk MA, Hochman S. (2005) Reversal of the circadian expression of tyrosine-hydroxylase but not nitric oxide synthase levels in the spinal cord of dopamine D3 receptor knockout mice. Neuroscience133: 353-357. [PMID:15878801]

33. Collins GT, Butler P, Wayman C, Ratcliffe S, Gupta P, Oberhofer G, Caine SB. (2012) Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats. Behav Pharmacol23 (3): 280-91. [PMID:22470105]

34. Cooper DC, Loeltzow TE, Xu M, Tonegawa S, White FJ, Wolf ME. (1996) Regulations of dopamine release and synthesis in dopamine D3R receptor knockout mice. (Abstract) Soc. Neurosci. Abst.22: 1319-.

35. Cox BA, Rosser MP, Kozlowski MR, Duwe KM, Neve RL, Neve KA. (1995) Regulation and functional characterization of a rat recombinant dopamine D3 receptor. Synapse21: 1-9. [PMID:8525456]

36. Crocq MA, Mant R, Asherson P, Williams J, Hode Y, Mayerova A, Collier D, Lannfelt L, Sokoloff P, Schwartz JC. (1992) Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet29: 858-860. [PMID:1362221]

37. Daly SA, Waddington JL. (1993) Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists. Neuropharmacology32: 509-510. [PMID:8321432]

38. Damsma G, Bottema T, Westerink BH, Tepper PG, Dijkstra D, Pugsley TA, MacKenzie RG, Heffner TG, Wikström H. (1993) Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. Eur J Pharmacol249: R9-10. [PMID:8287911]

39. Depoortere R, Perrault G, Sanger DJ. (1996) Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology (Berl)124: 231-240. [PMID:8740044]

40. Devoto P, Collu M, Muntoni AL, Pistis M, Serra G, Gessa GL, Diana M. (1995) Biochemical and electrophysiological effects of 7-OH-DPAT on the mesolimbic dopaminergic system. Synapse20: 153-155. [PMID:7570345]

41. Diaz J, Lévesque D, Lammers CH, Griffon N, Martres MP, Schwartz JC, Sokoloff P. (1995) Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience65 (3): 731-45. [PMID:7609872]

42. Diaz J, Pilon C, Le Foll B, Gros C, Triller A, Schwartz JC, Sokoloff P. (2000) Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J. Neurosci.20 (23): 8677-84. [PMID:11102473]

43. Dijkstra D, Rodenhuis N, Vermeulen ES, Pugsley TA, Wise LD, Wikström HV. (2002) Further characterization of structural requirements for ligands at the dopamine D(2) and D(3) receptor: exploring the thiophene moiety. J. Med. Chem.45 (14): 3022-31. [PMID:12086487]

44. Fishburn C, Bellili D, David C, Carmon S, Fuchs S. (1993) A novel short isoform of the D3 dopamine receptor generated by alternative splicing in the third cytoplasmic loop. J. Biol. Chem.268: 5872-5878. [PMID:8449953]

45. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G. (1994) Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther268: 417-426. [PMID:8301582]

46. Furman CA, Roof RA, Moritz AE, Miller BN, Doyle TB, Free RB, Banala AK, Paul NM, Kumar V, Sibley CD et al.. (2014) Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists. Eur Neuropsychopharmacol,  [Epub ahead of print]. [PMID:25583363]

47. Gainetdinov RR, Sotnikova TD, Grekhova TV, Rayevsky KS. (1996) In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol308: 261-269. [PMID:8858296]

48. Galaj E, Ananthan S, Saliba M, Ranaldi R. (2014) The effects of the novel DA D3 receptor antagonist SR 21502 on cocaine reward, cocaine seeking and cocaine-induced locomotor activity in rats. Psychopharmacology (Berl.)231 (3): 501-10. [PMID:24037509]

49. Gehlert DR, Gackenheimer SL, Seeman P, Schaus J. (1992) Autoradiographic localization of [3H]quinpirole binding to dopamine D2 and D3 receptors in rat brain. Eur J Pharmacol211: 189-194. [PMID:1351846]

50. Gilbert DB, Cooper SJ. (1995) 7-OH-DPAT injected into the accumbens reduces locomotion and sucrose ingestion: D3 autoreceptor-mediated effects?. Pharmacol Biochem Behav52: 275-280. [PMID:8577791]

51. Gilbert JG, Newman AH, Gardner EL, Ashby Jr CR, Heidbreder CA, Pak AC, Peng XQ, Xi ZX. (2005) Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse57 (1): 17-28. [PMID:15858839]

52. Giros B, Martres M-P, Sokoloff P, Schwartz J-C. (1990) cDNA cloning of the human dopaminergic D3 receptor and chromosome identification. C. R. Acad. Sci. III311: 501-508. [PMID:2129115]

53. Giros B, Martres MP, Pilon C, Sokoloff P, Schwartz JC. (1991) Shorter variants of the D3 dopamine receptor produced through various patterns of alternative splicing. Biochem. Biophys. Res. Commun.176: 1584-1592. [PMID:2039532]

54. Gobert A, Rivet JM, Audinot V, Cistarelli L, Spedding M, Vian J, Peglion JL, Millan MJ. (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther275: 899-913. [PMID:7473181]

55. Griffon N, Crocq MA, Pilon C, Martres MP, Mayerova A, Uyanik G, Burgert E, Duval F, Macher JP, Javoy-Agid F, Tamminga CA, Schwartz JC, Sokoloff P. (1996) Dopamine D3 receptor gene: organization, transcript variants and polymorphism associated with schizophrenia. Am. J. Med. Genet.67: 58-70. [PMID:8678117]

56. Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi JK, Jenkins BG, Luedtke RR, Newman AH. (2007) Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J. Med. Chem.50 (17): 4135-46. [PMID:17672446]

57. Hachimine P, Seepersad N, Ananthan S, Ranaldi R. (2014) The novel dopamine D3 receptor antagonist, SR 21502, reduces cocaine conditioned place preference in rats. Neurosci. Lett.569: 137-41. [PMID:24704326]

58. Heier RF, Dolak LA, Duncan JN, Hyslop DK, Lipton MF, Martin IJ, Mauragis MA, Piercey MF, Nichols NF, Schreur PJ et al.. (1997) Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites. J. Med. Chem.40 (5): 639-46. [PMID:9057850]

59. Heinrich T, Böttcher H, Gericke R, Bartoszyk GD, Anzali S, Seyfried CA, Greiner HE, Van Amsterdam C. (2004) Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J. Med. Chem.47 (19): 4684-92. [PMID:15341484]

60. Herroelen L, De Backer JP, Wilczak N, Flamez A, Vauquelin G, De Keyser J. (1994) Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res648: 222-228. [PMID:7922537]

61. Hoare SR, Coldwell MC, Armstrong D, Strange PG. (2000) Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues. Br. J. Pharmacol.130 (5): 1045-59. [PMID:10882389]

62. Hu R, Song R, Yang R, Su R, Li J. (2013) The dopamine D3 receptor antagonist YQA14 that inhibits the expression and drug-primed reactivation of morphine-induced conditioned place preference in rats. Eur. J. Pharmacol.,  [Epub ahead of print]. [PMID:24513519]

63. Jeanneteau F, Funalot B, Jankovic J, Deng H, Lagarde JP, Lucotte G, Sokoloff P. (2006) A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc. Natl. Acad. Sci. U.S.A.103 (28): 10753-8. [PMID:16809426]

64. Joseph JD, Wang YM, Miles PR, Budygin EA, Picetti R, Gainetdinov RR, Caron MG, Wightman RM. (2002) Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience112: 39-49. [PMID:12044470]

65. Kagaya T, Yonaga M, Furuya Y, Hashimoto T, Kuroki J, Nishizawa Y. (1996) Dopamine D3 agonists disrupt social behavior in rats. Brain Res721: 229-232. [PMID:8793104]

66. Kennedy JL, Billett EA, Macciardi FM, Verga M, Parsons TJ, Meltzer HY, Lieberman J, Buchanan JA. (1995) Association study of dopamine D3 receptor gene and schizophrenia. Am J Med Genet60: 558-562. [PMID:8825896]

67. Khroyan TV, Baker DA, Neisewander JL. (1995) Dose-dependent effects of the D3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning. Psychopharmacology (Berl)122: 351-357. [PMID:8657832]

68. Kling-Petersen T, Ljung E, Svensson K. (1994) The preferential dopamine autoreceptor antagonist (+)-UH232 antagonizes the positive reinforcing effects of cocaine and d-amphetamine in the ICSS paradigm. Pharmacol Biochem Behav49: 345-351. [PMID:7824548]

69. Kling-Petersen T, Ljung E, Svensson K. (1995) Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain. J Neural Transm Gen Sect102: 209-220. [PMID:8788069]

70. Koeltzow T, Cooper DC, Hu X-T, Xu M, Tonegawa S, White FJ. (1995) In vivo effects of dopaminergic ligands on dopamine D3 receptor deficient mice. (Abstract) Soc. Neurosci. Abst.21: 364-.

71. Kreiss DS, Bergstrom DA, Gonzalez AM, Huang KX, Sibley DR, Walters JR. (1995) Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur J Pharmacol277: 209-214. [PMID:7493610]

72. Kurashima M, Yamada K, Nagashima M, Shirakawa K, Furukawa T. (1995) Effects of putative dopamine D3 receptor agonists, 7-OH-DPAT, and quinpirole, on yawning, stereotypy, and body temperature in rats. Pharmacol Biochem Behav52: 503-508. [PMID:8545466]

73. Lacroix LP, Ceolin L, Zocchi A, Varnier G, Garzotti M, Curcuruto O, Heidbreder CA. (2006) Selective dopamine D3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases. J. Neurosci. Methods157 (1): 25-31. [PMID:16697046]

74. Lacroix LP, Hows ME, Shah AJ, Hagan JJ, Heidbreder CA. (2003) Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacology28 (5): 839-49. [PMID:12637956]

75. Lahti RA, Roberts RC, Tamminga CA. (1995) D2-family receptor distribution in human postmortem tissue: an autoradiographic study. Neuroreport6: 2505-2512. [PMID:8741751]

76. Landwehrmeyer B, Mengod G, Palacios JM. (1993) Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur J Neurosci5: 145-153. [PMID:8261096]

77. Landwehrmeyer B, Mengod G, Palacios JM. (1993) Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res Mol Brain Res18: 187-192. [PMID:8097550]

78. Lannfelt L, Sokoloff P, Martres MP, Pilon C, Giros B, Jonsson E, Sedvall G, Schwartz JC. (1992) Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr. Genet.2: 249-256.

79. Le Foll B, Diaz J, Sokoloff P. (2005) Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice. Life Sci76: 1281-1296. [PMID:15642598]

80. Lejeune F, Millan MJ. (1995) Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. Eur J Pharmacol275: R7-R9. [PMID:7768288]

81. Leriche L, Schwartz JC, Sokoloff P. (2003) The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology45 (2): 174-81. [PMID:12842123]

82. Levant B, Grigoriadis DE, DeSouza EB. (1992) Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain. J Pharmacol Exp Ther262: 929-935. [PMID:1356154]

83. Levant B, Vansell NR. (1997) In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsychopharmacology17: 67-71. [PMID:9252981]

84. Liu JC, Cox RF, Greif GJ, Freedman JE, Waszczak BL. (1994) The putative dopamine D3 receptor agonist 7-OH-DPAT: lack of mesolimbic selectivity. Eur J Pharmacol264: 269-278. [PMID:7698165]